Document:

Prepared by R.R. Donnelley Financial -- Agreement with Peter L. Myers

  
 Exhibit 10.40 
  
 EMPLOYMENT AGREEMENT 
  
 THIS EMPLOYMENT AGREEMENT (this
“Agreement”) is made by and between Bristol-Myers Squibb Pharma Research Labs L.L.C., a Delaware limited liability company (hereinafter the “Company”), and Peter L. Myers (hereinafter “Employee”)
and shall become effective upon the date of the latest signature hereto. 
  
 RECITALS 
  
 WHEREAS, this Agreement is entered into in connection with that certain Purchase Agreement, dated February 8, 2002 (the “Purchase
Agreement”), between Deltagen, Inc. (“Deltagen”), a Delaware corporation, and Bristol-Myers Squibb Company, a Delaware corporation, pursuant to which the Company will become a wholly owned subsidiary of Deltagen;

  
 WHEREAS, the Company and Employee wish to set forth in this Agreement the terms and conditions under which Employee will
continue to be employed by the Company; and 
  
 WHEREAS, the Company wishes to be assured that Employee will be available to the
Company for at least an additional two years after the Closing Date (as such term is defined in the Purchase Agreement). 
  
 NOW,
THEREFORE, the Company and Employee, in consideration of the mutual promises set forth herein, agree as follows: 
  
 ARTICLE I.

  
 EMPLOYMENT DUTIES 
  
 A.    Title/Responsibilities.    Employee hereby accepts employment with the Company pursuant to the terms and conditions hereof. Employee agrees to serve the Company in
the position of Executive Vice President and Site Director. Employee shall have the powers and duties commensurate with such position. It is agreed and understood that the Company may reassign Employee to another position consistent with
Employee’s knowledge and experience within its organization during the term of this Agreement, but that no relocation shall be required of Employee without Employee’s prior consent. 
  

B.    Full Time Attention.    Employee shall devote his best efforts and his full business time and attention to the performance of
the services customarily incident to such office and to such other services as the Company may reasonably request. 
  
 C.    Other Activities.    Except upon the prior written consent of the Company, Employee shall not during the period of employment engage, directly or indirectly, in any other business
activity (whether or not pursued for pecuniary advantage) that is or may be competitive with, or that might place him in a competing position to that of the Company or any other corporation or entity that directly or indirectly controls, is
controlled by, or is under common control with the
 
 

 1 

 
Company (an “Affiliated Company”), provided that Employee may own less than one percent (1%) of the outstanding securities of any such publicly traded competing corporation.

  
 ARTICLE II. 
  
 COMPENSATION 
  
 A.    Base Salary.    Employee shall receive
a Base Salary at an annual rate of Two Hundred Ninety Thousand dollars ($290,000), payable in accordance with the Company’s customary payroll practices. The Company shall provide Employee with annual performance reviews, and, thereafter,
Employee shall be entitled to such Base Salary as the Company may from time to time establish in its sole discretion. 
  
 B.    Bonuses.    Employee’s entitlement to incentive bonuses from the Company is discretionary and shall be determined by Deltagen’s Board, Compensation Committee or Chief Executive
Officer in good faith based upon the extent to which Employee’s individual performance objectives and the Company’s profitability objectives and other financial and nonfinancial objectives are achieved during the applicable bonus period.

  
 C.    Stock Options.    Upon the Closing Date and subject to approval of the
Deltagen’s Board of Directors, Employee will be granted a stock option under the Deltagen’s 2000 Stock Incentive Plan to purchase 175,000 shares of the Deltagen’s common stock (the “Option”). To the maximum extent possible,
the Option shall be an Incentive Stock Option as such term is defined in Section 422 of the Internal Revenue Code of 1986, as amended. The Option will be governed by and granted pursuant to a separate stock option agreement. The exercise price per
share of the Option will be equal to the fair market value of the Deltagen’s common stock established on the date of grant. The Option will be subject to vesting over four (4) years so long as Employee continues to be employed with the Company,
according to the following schedule: Twenty-five percent (25%) of such shares shall vest and become exercisable twelve (12) months following the grant date, with an additional 1/48 of such shares vesting at the end of each monthly period thereafter.

  
 D.    Retention Bonus.    If Employee remains an employee of the Company through
November 1, 2002, he shall be entitled to a cash retention bonus of $150,000. 

	

 E.    Withholdings.    All compensation and benefits to Employee
hereunder shall be subject to all federal, state, local and other withholdings and similar taxes and payments required by applicable law. 
  
 ARTICLE III. 
  
 EXPENSE ALLOWANCES AND FRINGE BENEFITS 
  
 A.    Vacation.    Employee shall receive three (3) weeks of annual paid vacation during the term of this
Agreement. 
 

 2 

  
 B.    Benefits.    During the term of this
Agreement, the Company will provide Employee with the opportunity to participate in the standard benefits plans currently available to other similarly situated employees, including medical, dental and vision insurance, subject to any eligibility
requirements imposed by such plans. The amount and extent of benefits to which Employee is entitled shall be governed by the specific benefit plan as it may be amended from time to time. 
  
 C.    Business Expense Reimbursement. During the term of this Agreement, Employee shall be entitled to receive proper reimbursement for all reasonable
out-of-pocket expenses incurred by him (in accordance with the policies and procedures established by the Company for similarly situated employees) in performing services hereunder, provided Employee properly accounts therefor. 

 
 ARTICLE IV. 
  
 CONFIDENTIALITY 
  
 A.    Proprietary
Information.    Employee shall sign, or has signed, an Employee’s Proprietary Information and Invention Assignment Agreement (the “Confidentiality Agreement”) substantially in the form attached hereto as
Exhibit A. Employee hereby represents and warrants to the Company that he or she has complied with all obligations under the Confidentiality Agreement and agrees to continue to abide by the terms of the Confidentiality Agreement and further agrees
that the provisions of the Confidentiality Agreement shall survive any termination of this Agreement or of Employee’s employment relationship with the Company. 
  
 B.    Return of Property.    All documents, records, apparatus, equipment and other physical property which is furnished to or obtained by
Employee in the course of his employment with the Company shall be and remain the sole property of the Company. Employee agrees that, upon the termination of his employment, he shall return all such property (whether or not it pertains to
Proprietary Information as defined in the Proprietary Information and Inventions Agreement), and agrees not to make or retain copies, reproductions or summaries of any such property. 
  
 ARTICLE V. 
  
 TERM AND TERMINATION 
  
 A.    Term of Agreement.    Unless otherwise terminated by the Company in accordance with this Agreement,
this Agreement and Employee’s employment with the Company under this Agreement shall commence at the Closing Date and shall continue to and including the date which is two (2) years thereafter (the “Employment Term”).

  
 B.    Termination Upon Death of Employee. The Employment Term shall terminate automatically upon the
death of Employee. In such event, the Company shall pay to Employee’s beneficiaries or his estate, as the case may be, any accrued Base Salary, any bonus compensation to the extent earned, any vested deferred compensation (other than pension
plan or profit-sharing plan benefits which will be paid in accordance with the applicable plan), any benefits under any 
 

 3 

 plans of the Company in which Employee is a participant to the full extent of Employee’s rights under such plans, any accrued vacation pay and any
appropriate business expenses incurred by Employee in connection with his duties hereunder, all to the date of termination (collectively “Accrued Compensation”), but no other compensation or reimbursement of any kind, including,
without limitation, severance compensation, and thereafter, the Company’s obligations hereunder shall terminate. 
  
 C.    Termination Upon Disability of Employee.    If Employee is prevented from properly performing his duties hereunder by reason of any physical or mental incapacity for a period of more than
180 days in the aggregate in any 365-day period, then, to the extent permitted by law, the Company may terminate the employment on the 180th day of such incapacity. In such event, the Company shall pay to Employee all Accrued Compensation, and shall
continue to pay to Employee the Base Salary then in effect until such time as Employee shall become entitled to receive disability insurance payments under the disability insurance policy maintained by the Company. 
  
 D.    Termination for Cause.    The Company may terminate Employee’s employment for Cause (as
defined below) without liability at any time with or without advance notice to Employee. The Company shall pay Employee all Accrued Compensation, but no other compensation or reimbursement of any kind, including without limitation, severance
compensation, and thereafter the Company’s obligations hereunder shall terminate. Termination shall be for “Cause” in the event of the occurrence of any of the following: (a) any intentional action or intentional failure to act
by Employee which was performed in bad faith and to the material detriment of the Company; (b) Employee intentionally refuses or intentionally fails to act in accordance with any lawful and proper direction or order of the Company; (c) Employee
willfully and habitually neglects the duties of employment; or (d) Employee is convicted of a felony crime involving moral turpitude. 
  
 E.    Termination At Will.    The Company may terminate your employment at any time for any reason not specified in Article 5.D above, or for no reason, without further obligation or liability
(except as set forth below). If the Company elects to terminate Employee during the Employment Term pursuant to this Article 5.E, the Company shall pay to Employee all Accrued Compensation and shall continue to pay to Employee as provided herein
Employee’s Salary then in effect for six (6) months from the date of such termination as severance compensation. Upon payment of the severance benefits described herein, all obligations of the Company (or its successor) shall terminate. Any
unvested stock options held by Employee as of the date of Employee’s termination of employment shall be accelerated by six (6) months. 
  
 During the period when such severance compensation is being paid to Employee, Employee shall not (i) engage, directly or indirectly, in any other business activity that is competitive with the current technology of
the Company or any Affiliated Company (provided that Employee may own less than one percent (1%) of the outstanding securities of any publicly traded corporation), or (ii) hire, solicit, or attempt to hire on behalf of himself or any other party any
employee or exclusive consultant of the Company. If the Company terminates this Agreement or the employment of Employee with the Company other than pursuant to Articles 5.B, 5.C or 5.D, then this Article 5.E shall apply. 
 

 4 

  
 ARTICLE VI. 
  
 GENERAL PROVISIONS 
  
 A.    Governing
Law.    This Agreement shall be governed and construed in accordance with the laws of the State of California without regard to any applicable conflicts of law. 
  
 B.    Assignment; Binding Agreement. 
  
 1.    Employee may not assign, pledge or encumber his interest in this Agreement or any part thereof. 
  
 2.    This Agreement shall inure to the benefit of and be enforceable by Employee’s personal or legal representatives, executors, administrators, successors, heirs, distributee, devisees and legatees. If Employee
should die while any amount is at such time payable to him hereunder, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to Employee’s devisee, legates or other designee or, if there
be no such designee, to his estate. 
  
 C.    No Waiver of Breach.    The waiver by
any party of the breach of any provision of this Agreement shall not be deemed to be a waiver of any subsequent breach. 
  
 D.    Notice.    For the purposes of this Agreement, notices and all other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given when
delivered or mailed by certified or registered mail, return receipt requested, postage prepaid, addressed to the respective addresses set forth below or to such other address as either party may have furnished to the other in writing in accordance
herewith, except that notice of change of address shall be effective only upon receipt. 
  
 
	 To the Company:
 	    	 c/o Deltagen, Inc.
 
	  	    	 740 Bay Road
 
	  	    	 Redwood City, CA 94063-2469
 
	  	    	 Attention:    Vice President, Human Resources
 
	  	    	 Fax No.:    (650) 569-5273
 
	  	    	 Telephone No.:    (650) 569-5100
 
	  	    	  
	 To Employee:
 	    	 Peter L. Myers
 
	  	    	 4570 Executive Drive, Suite 400
 
	  	    	 San Diego, CA 92121
 
	  	    	 Fax No:    (858)625-6487
 
	  	    	 Telephone No.:    (858) 625-6487
 

 
  
 E.    Modification; Waiver; Entire
Agreement.    No provisions of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing signed by Employee and such officer as may be specifically designated
by the Company. No waiver by either party hereto at any time of any breach by the other party of, or compliance 
 

 5 

  
 with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of
similar or dissimilar provisions or conditions at the same or any prior or subsequent time. This Agreement constitutes the entire agreement of the parties with respect to the subject matter hereof and no agreements or representations, oral or
otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement. 
  
 F.    Validity.    The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this
Agreement, which shall remain in full force and effect. 
  
 G.    Termination of Prior
Agreements.    Employee acknowledges that the Employment Agreement, dated October 5, 1999, between the Company and Employee is hereby terminated and that the terms and conditions thereof, together with any and all prior
undertakings and agreements of the Company and Employee with respect to the subject matter hereof, are superceded in their entirety by this Agreement. 
  
 H.    Arbitration.    Any dispute or claim arising out of or in connection with this Agreement will be finally settled by binding arbitration in accordance with Exhibit B
hereto. This Article 6.H shall not apply to the Confidentiality Agreement. 
  
 I.    Employee
Acknowledgment.    Employee acknowledges (a) that he has consulted with or has had the opportunity to consult with independent counsel of his own choice concerning this Agreement, and has been advised to do so by the Company,
and (b) that he has read and understands the Agreement, is fully aware of its legal effect, and has entered into it freely based on his own judgment. 
  
 J.    Remedies. 
  
 1.    Injunctive
Relief.    The parties agree that the services to be rendered by Employee hereunder are of a unique nature and that in the event of any breach or threatened breach of any of the covenants contained herein, the damage or
imminent damage to the value and the goodwill of the Company’s business will be irreparable and extremely difficult to estimate, making any remedy at law or in damages inadequate. Accordingly, the parties agree that the Company shall be
entitled to injunctive relief against Employee in the event of any breach or threatened breach of any such provisions by Employee, in addition to any other relief (including damages) available to the Company under this Agreement or under law.

  
 2.    Exclusive.    Both parties agree that the remedy specified in Article
6.J.1 above is not exclusive of any other remedy for the breach by Employee of the terms hereof. 
  
 K.    Counterparts.    This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same agreement and shall become effective when two or more
counterparts have been signed by each of the parties and delivered to the other parties, it being understood that all parties need not sign the same counterpart. 
  
 [Signature Page Follows] 
 

 6 

  
 Executed by the parties as of the dates set forth below. 
  
  

	 	BR
	ISTOL-MYERS SQUIBB PHARMA 
 

	 	RE
	SEARCH LABS L.L.C. 
 

  
  
 
	 Date:    February 16, 2002
 	  	 By:    /s/    RICHARD H. HAWKINS
 
Name:    Richard H. Hawkins
 Title:    Chief Financial Officer
 
	 
	  	  	 EMPLOYEE
 
	 
	 Date:    February 4, 2002
 	  	 /s/    PETER L. MYERS
 
Name:    Peter L. Myers
 

 
  
 

 7<PAGE>

                                                                   Exhibit 10.39

January 28, 2002

Brian W. Metcalf, Ph.D.
297 Lakeview Place
Moraga, CA 94556

Dear Brian:

This letter sets forth the agreement (the "Agreement") that Kosan Biosciences,
Inc. (the "Company") is offering to you to aid in your employment transition.

     1. Resignation. Your last day as an employee and officer of the Company,
including as a member of any committees, will be January 29, 2002 (the
"Resignation Date").

     2. Accrued Salary and Vacation. On the Resignation Date, the Company will
pay you all accrued salary, and all accrued and unused vacation earned through
the Resignation Date, subject to standard payroll deductions and withholdings.
You are entitled to these payments whether or not you sign this Agreement.

     3. Expense Reimbursements. You agree that within ten (10) business days of
the Resignation Date, you will submit your final documented expense
reimbursement statement reflecting all business expenses you incurred through
the Resignation Date, if any, for which you seek reimbursement. The Company will
reimburse you for these expenses pursuant to its regular business practice.

     4. Consulting Services.

          (a) Services. You agree to serve as a consultant to the Company as a
member of its Scientific Advisory Board, under the terms specified herein and
the attached "Scientific Advisory Board Member Agreement" (Exhibit A). During
the Consulting Period, you will report directly to the Chief Executive Officer
("CEO") or as otherwise specified by the CEO.

          (b) Term. This consulting relationship commences on the Resignation
Date and continues for one year ("Consulting Period"). If at any time during the
Consulting Period the Company terminates your status as a Scientific Advisory
Board member without Cause (as that term is defined in your March 17, 2000
Employment Agreement), or if a full-time employer or equivalent requires you as
a condition of employment not to serve on the Company's Scientific Advisory
Board due to the potential for conflict of interest and the Company is informed
of this condition in writing by such an employer, your status as a member and
your obligations under Sections (I)(1) and (I)(2) of the Scientific Advisory
Board Member Agreement

<PAGE>

Brian Metcalf
Page 2

shall cease; however, your remaining obligations under the Scientific Advisory
Board Member Agreement (including without limitation Sections (I)(3) and (I)(4))
and this Agreement shall remain in full force and effect, and the Company shall
continue to provide you with the "Severance and Consulting Compensation"
described in Section 5 below under the terms and conditions stated herein.

     5. Severance and Consulting Compensation.

          (a) Payments. Following the Resignation Date, the Company will make
payments to you in the form of continuation of your base salary in effect on the
Resignation Date for twelve months in equal monthly installments. The Company's
obligation to make such payments shall: (i) be reduced by an amount equal to all
amounts that you become eligible to receive for any regularly scheduled or
periodic part-time work (whether as an employee, consultant, adviser, or
otherwise); and (ii) cease as of the date that you commence full-time employment
or its equivalent with another business entity. Days of work actually provided
to any one entity that exceed more than two in the year following the
Resignation Date will be considered regularly scheduled. You agree to notify the
Company within three business days of your acceptance of any such full or
part-time employment or equivalent and the amount of services actually provided.

          (b) Benefits. As provided by the federal COBRA law and by the
Company's current group health insurance policies, you will be eligible to
continue your health insurance benefits at your own expense for up to eighteen
(18) months following the Resignation Date and, later, to convert to an
individual policy if you wish. You will be provided with a separate notice of
your COBRA rights. If you elect continued coverage under COBRA, the Company will
pay your COBRA premiums necessary to continue your current coverage through the
termination of the Consulting Period. The Company's obligation to make these
payments will cease immediately if you become eligible for other health
insurance benefits at the expense of a new employer. You agree to notify the
Company within three business days of your acceptance of such employment.

          (c) Stock Option. The vesting of the option to purchase 100,000 shares
(300,000 shares post split) subject to the option described in Section 3 of the
Employment Agreement made as of March 17, 2000 between the Company and you (the
"Employment Agreement," attached hereto as Exhibit B) shall change such that the
option will continue to vest for 1/96thth of the shares for each month of the
Consulting Period. All rights and obligations with respect to options will be
governed by all applicable stock option plan documents and stock option
agreements. You acknowledge that the Company is not making any representation
regarding the tax treatment of your options and that you have been advised by
the Company to seek independent tax advice on the matter.

          (d) Promissory Notes. As part of this Agreement, your Resignation Date
will be considered an Event of Default under the Promissory Note (the "Prior
Note") executed by you

<PAGE>

Brian Metcalf
Page 3

on May 30, 2000 (attached hereto as Exhibit C), to have occurred due to the
Company's termination of Employee employment with the Company without cause.
Attached as Exhibit D is a new Promissory Note reflecting the terms specified in
the Prior Note upon such an Event of Default. Your note executed on April 19,
2001 in connection with a stock option exercise shall remain unaffected by this
Agreement.

          (e) Taxes and Withholding. The Company will not withhold from any
payments made to you any amount for taxes, social security or other payroll
deductions. The Company will issue you a Form 1099 with respect to such
payments. You acknowledge that you will be entirely responsible for payment of
any such taxes, and you hereby indemnify and hold harmless the Company from any
liability for any taxes, penalties or interest that may be assessed by any
taxing authority with respect to all compensation you receive under this
Agreement, with the exception of the employer's share of social security, if
any.

          (f) Other Compensation or Benefits. You acknowledge that, except as
expressly provided in this Agreement, you will not receive from the Company any
additional compensation, severance, stock option vesting, or benefits, including
but not limited to any severance payment, benefits, or stock vesting
acceleration described in Section 8 of the Employment Agreement.

     6. Return of Company Property. On the Resignation Date, you agree to return
to the Company all Company documents (and all copies thereof) and other Company
property that you have had in your possession at any time, including, but not
limited to, Company files, notes, drawings, records, business plans and
forecasts, financial information, specifications, training materials,
computer-recorded information, tangible property including, but not limited to,
computers and related equipment, credit cards, entry cards, identification
badges and keys; and any materials of any kind that contain or embody any
proprietary or confidential information of the Company (and all reproductions
thereof). You may retain such documents, property, and materials during the
Consulting Period only to the extent approved by the Company and you shall
return them immediately upon written request from the Company.

     7. Proprietary Information and Non-Competition Obligations. You acknowledge
and agree to your continuing obligations under your Employee Proprietary
Information and Invention Assignment Agreement (Exhibit E) both during and after
the Consulting Period, including without limitation paragraph 6(f) and the
non-solicitation obligations in paragraph 6(g) of such agreement. You agree not
to use or disclose any confidential or proprietary information of the Company
without prior written authorization from a duly authorized representative of the
Company.

     8. Nondisparagement. You agree not to disparage the Company or its
officers, directors, employees, shareholders, parents, subsidiaries, affiliates,
and agents, in any manner likely to be harmful to them or their business,
business reputation or personal reputation;

<PAGE>

Brian Metcalf
Page 4

provided that you shall respond accurately and fully to any question, inquiry,
or request for information when required by legal process.

     9. Consequences of Breach. You agree that in the event that you breach
Section 4, 6, 7, or 8 of this Agreement, you breach your obligations under your
Employee Proprietary Information and Invention Assignment Agreement or the
Scientific Advisory Board Member Agreement, or if the Company wishes to
terminate your status as a member of the Scientific Advisory Board for "Cause"
(as such term is defined in paragraph 10 of the Employment Agreement), in
addition to any other remedies that the Company may have, any outstanding
obligations of the Company under this Agreement shall immediately terminate, the
stock option vesting described in Section 5(c) will immediately cease, and the
date of such breach will be considered an Event of Default under the Prior Note
caused by a voluntary termination and a Event of Default under Section 4(d) of
the Promissory Note. This Agreement, and the releases contained in this
Agreement, shall nonetheless remain in full force and effect.

     10. Confidentiality. The provisions of this Agreement will be held in
strictest confidence by you and the Company and will not be publicized or
disclosed in any manner whatsoever; provided, however, that: (a) you may
disclose this Agreement to your immediate family; (b) the parties may disclose
this Agreement in confidence to their respective attorneys, accountants,
auditors, tax preparers, and financial advisors; (c) the Company may disclose
this Agreement as necessary to fulfill standard or legally required corporate
reporting or disclosure requirements; and (d) the parties may disclose this
Agreement insofar as such disclosure may be necessary to enforce its terms or as
otherwise required by law. In particular, and without limitation, you will not
disclose the provisions of this Agreement to any current or former Company
employee or any other Company personnel.

     11. Dispute Resolution. Unless otherwise prohibited by law or specified
below, all disputes, claims and causes of action in law or equity arising from
or relating to this Agreement or its enforcement, performance, breach or
interpretation shall be resolved solely and exclusively by final and binding
confidential arbitration through American Arbitration Association ("AAA") to be
held in San Francisco, California, under the then-existing AAA arbitration rules
for employment dispute resolution. Nothing in this section, however, is intended
to prevent either party from obtaining injunctive relief in court to prevent
irreparable harm pending the conclusion of any such arbitration.

     12. Release of Claims. In exchange for the consideration under this
Agreement to which you would not otherwise be entitled, you hereby release,
acquit and forever discharge the Company, its parents and subsidiaries, and
their officers, directors, agents, servants, employees, attorneys, shareholders,
successors, assigns and affiliates, of and from any and all claims, liabilities,
demands, causes of action, costs, expenses, attorneys fees, damages, indemnities
and obligations of every kind and nature, in law, equity, or otherwise, known
and unknown, suspected and unsuspected, disclosed and undisclosed, arising out
of or in any way related to agreements, events, acts or conduct at any time
prior to and including the execution date of this

<PAGE>

Brian Metcalf
Page 5

Agreement, including but not limited to: all such claims and demands directly or
indirectly arising out of or in any way connected with your employment with the
Company or the termination of that employment; claims or demands related to
salary, bonuses, commissions, stock, stock options, or any other ownership
interests in the Company, vacation pay, fringe benefits, expense reimbursements,
severance pay, or any other form of compensation; claims pursuant to any
federal, state or local law, statute, or cause of action including, but not
limited to, the federal Civil Rights Act of 1964, as amended; the federal Age
Discrimination in Employment Act of 1967, as amended ("ADEA"); the federal
Americans with Disabilities Act of 1990; the California Fair Employment and
Housing Act, as amended; tort law; contract law; wrongful discharge;
discrimination; harassment; fraud; defamation; emotional distress; and breach of
the implied covenants of good faith and fair dealing.

     13. ADEA Waiver. You acknowledge that you are knowingly and voluntarily
waiving and releasing any rights you may have under the ADEA. You also
acknowledge that the consideration given for the waiver and release in the
preceding paragraph hereof is in addition to anything of value to which you were
already entitled. You further acknowledge that you have been advised by this
writing, as required by the ADEA, that: (a) your waiver and release do not apply
to any rights or claims that may arise after the execution date of this
Agreement; (b) you have been advised hereby that you have the right to consult
with an attorney prior to executing this Agreement; (c) you have twenty-one (21)
days to consider this Agreement (although you may choose to voluntarily execute
this Agreement earlier); (d) you have seven (7) days following the execution of
this Agreement by the parties to revoke the Agreement; and (e) this Agreement
shall not be effective until the date upon which the revocation period has
expired, which shall be the eighth day after this Agreement is executed by you
(the "Effective Date").

     14. Waiver. In giving the release herein, which includes claims which may
be unknown to you at present, you acknowledge that you have read and understand
Section 1542 of the Civil Code of the State of California which reads as
follows: "A general release does not extend to claims which the creditor does
not know or suspect to exist in his favor at the time of executing the release,
which if known by him must have materially affected his settlement with the
debtor." You hereby expressly waive and relinquish all rights and benefits under
that section and any law of any jurisdiction of similar effect with respect to
your release of any claims you may have against the Company.

     15. Miscellaneous. This Agreement, including all exhibits, constitutes the
complete, final and exclusive embodiment of the entire agreement between you and
the Company with regard to the subject matter hereof. In the event of any
conflict between this Agreement and one of the exhibits, this Agreement shall
control. It is entered into without reliance on any promise or representation,
written or oral, other than those expressly contained herein, and it supersedes
any other such promises, warranties or representations. This Agreement may not
be modified or amended except in a written agreement signed by both you and a
duly authorized officer of the Company. This Agreement will bind the heirs,
personal representatives, successors and assigns of both you and the Company,
and inure to the benefit of both you and the Company, their heirs,

<PAGE>

Brian Metcalf
Page 6

successors and assigns. The failure to enforce any breach of this Agreement will
not be deemed to be a waiver of any other or subsequent breach. For purposes of
construing this Agreement, any ambiguities will not be construed against either
party as the drafter. If any provision of this Agreement is determined to be
invalid or unenforceable, in whole or in part, this determination will not
affect any other provision of this Agreement and the provision in question will
be modified by the court so as to be rendered enforceable in a manner consistent
with the intent of the parties insofar as possible. This Agreement will be
deemed to have been entered into and will be construed and enforced in
accordance with the laws of the State of California as applied to contracts made
and to be performed entirely within California. This Agreement may be executed
in counterparts or with facsimile signatures, which will be deemed equivalent to
originals.

If this Agreement is acceptable to you, please sign below and on Exhibit A and
Exhibit D, and return the originals of each to me.

I wish you luck in your future endeavors and look forward to our continuing
relationship.

Sincerely,

KOSAN BIOSCIENCES, INC.

By:   /s/ Michael S. Ostrach
   --------------------------------------------------
       Michael S. Ostrach
       President and Chief Operating Officer

Exhibit A -       Scientific Advisory Board Member Agreement
Exhibit B -       Employment Agreement
Exhibit C -       Prior Note
Exhibit D -       Promissory Note
Exhibit E -       Employee Proprietary Information and Invention Assignment
                  Agreement

UNDERSTOOD AND AGREED:

By:   /s/ Brian W. Metcalf, Ph.D.
   --------------------------------------------------
       Brian W. Metcalf, Ph.D.

Date:  January 23, 2002

<PAGE>

                                    EXHIBIT A

                   SCIENTIFIC ADVISORY BOARD MEMBER AGREEMENT

KOSAN Biosciences Inc.
3832 Bay Center Place
Hayward, CA  94404
Tel: 510-732-8400
Fax: 510-732-8401

--------------------------------------------------------------------------------

January 28, 2002

Brian W. Metcalf, Ph.D.
297 Lakeview Place
Moraga, CA 94556

Re:   Scientific Advisory Board Member Agreement

Dear Brian,

Kosan Biosciences, Inc. (the "Company"), desires to appoint you as a Scientific
Advisory Board ("SAB") member, effective as of the Resignation Date provided in
the letter agreement (the "Letter Agreement") to which this agreement is
attached, under the following terms and conditions (the "SAB Agreement").

I. Expectations

1. The Company is engaged in the business of, among other things, the discovery,
design, and development of pharmaceuticals, with a current focus in the area of
biosynthesis of polyketides and other natural products and the chemical
modification of such compounds (the "Field"). Members of the SAB are more than
consultants: they are partners in achieving the goal of establishing a premier
and profitable Company. As a member of the SAB, you are expected to devote your
time, intellect, and best efforts to achieving the goals of the Company in the
Field and to advise the Company in the areas of your professional expertise that
relate or may relate to the Company. A member of the SAB is expected to devote
the equivalent of six (6) to ten (10) working days per year of service to the
Company.

2. During the term of this SAB Agreement, you may be involved in the following
activities, among others, to further the goals of the Company:

     (a)  consulting with representatives of the Company;

<PAGE>

     (b)  assessing or overseeing specific projects in which you have an
          interest and expertise;
     (c)  introducing projects to be developed at or outside the Company;
     (d)  assistance and advice to the Company in obtaining funding;
     (e)  collaboration with the Company in projects of mutual interest; and
     (f)  advice and assistance in the recruitment of personnel.

3. During the term of this SAB Agreement, other than for the Company, you agree
not to engage in any employment or activity (whether as an employee, consultant,
adviser, or otherwise) in the "Field" or otherwise competing with the Company.

4. You warrant that your responsibilities and activities as of the Resignation
Date do not conflict with this SAB Agreement, and you agree that during the term
of this SAB Agreement you will not accept work or enter into a contract or
accept an obligation inconsistent or incompatible with your obligations under
this SAB Agreement.

5. If you have a conflict of interest, or a potential conflict of interest, with
respect to any matter presented at a meeting of the Scientific Advisory Board or
in other interactions with the Company, you will state such, and excuse yourself
from the discussion of such matter.

6. You agree that you are an independent contractor, not an employee of the
Company.

7. You will have no responsibilities or authority as a consultant to the Company
other than as provided herein. You agree not to represent or purport to
represent the Company in any manner whatsoever to any third party unless
authorized by the Company, in writing, to do so.

II.  Compensation and Expenses
     -------------------------

1. As full consideration for the services performed by you under this SAB
Agreement, the Company agrees to compensate you as provided in Section 5 of the
Letter Agreement.

2. You will be reimbursed for out-of-pocket expenses approved in advance in
writing by the Company that you incur under the terms of this SAB Agreement.
These allowed expenses will be reimbursed in accordance with the Company's
policy.

III. Term and Termination
     --------------------

The term of this SAB Agreement shall be the same as the Consulting Period
described in paragraph 4 of the Letter Agreement. The Company may terminate your
status as a

<PAGE>

SAB Member by giving five (5) days written notice, with or without cause.
Sections IV and V of this SAB Agreement shall survive termination of this SAB
Agreement.

IV. Patents and Confidentiality
    ---------------------------

1. You agree that any inventions, innovations, suggestions, methods, processes,
improvements, ideas, and discoveries ("Items") made or conceived or reduced to
practice solely or jointly with others in the course of providing services to
the Company pursuant to this SAB Agreement shall be promptly disclosed to the
Company and shall become the sole property of the Company without obligation of
the Company to pay any royalty or other consideration. You further agree that
any such Item that relates to the Company's objectives made or conceived by you
in other capacities will be brought to the attention of the Company, and that
you will support in good faith the Company's attempts to enter into agreements
so the Company may use and obtain the rights to use such Item.

2. You agree that you will not disclose without prior written consent of the
Company, any information confidential to the Company or its affiliates.
"Confidential Information" in this context means all data, information, or trade
secrets (including all cell cultures or chemical or biological materials)
relating to the Company's technical programs or business plans, that you know or
have reason to know is regarded as confidential by the Company. This SAB
Agreement does not apply to confidential information that: (i) has become part
of the public domain, unless by breach of the SAB Agreement, (ii) the Company
has publicly disclosed, (iii) was known by you prior to the date of its
disclosure to you by the Company as shown by your written records, (iv) you
received from a source having no duty of confidentiality to the Company, or (v)
directly resulted from work performed in your laboratory and regarding which you
have given the Company written notice as provided in Section VII before
publication or disclosure.

3. You agree that, during the term of this SAB Agreement, you will not disclose
to the Company any proprietary information, such as trade secret information,
that is confidential to any third party.

4. At the Company's request, you will promptly return to the Company all
confidential technical or business information or materials relating to the
Company's business. Upon the Company's request, you will provide in writing
detailed summaries of research or evaluations performed by you for the Company.

<PAGE>

V. Publication
   -----------

The Company and you anticipate that information and data resulting from any
research you may perform in collaboration with the Company or on behalf of the
Company will be published or otherwise disclosed when appropriate to do so. You
agree to submit any such information and data to the Company at least thirty
(30) days prior to submission for publication or ninety (90) days before written
or oral public disclosure. You further agree to delay publication of such
information and data if the Company determines for business (for a period not to
exceed six (6) months) or proprietary (indefinitely) reasons that such a delay
is necessary. If the Company determines that such information and data contains
information and data owned by the Company, you agree to remove such Company
information and data from the proposed publication or disclosure upon the
Company's request.

VI. Entire Agreement and Modifications of the Agreement
    ---------------------------------------------------

This SAB Agreement, along with the Letter Agreement and its exhibits,
constitutes the complete, final and exclusive embodiment of the entire agreement
between you and the Company with regard to the subject matter hereof. No
modification of the SAB Agreement shall be valid unless made in writing and
signed by the parties hereto.

VII. Severable Provisions
     --------------------

The provisions of this SAB Agreement are severable, and if any of the provisions
of this SAB Agreement are determined to be illegal or otherwise unenforceable in
whole or in part, the remaining provisions and any partially enforceable
provisions shall be binding and enforced.

VIII. Captions
      --------

The captions of this SAB Agreement are used only for convenience and reference,
and do not define, limit, or describe the scope or intent of the terms hereof.

IX. Governing Law
    -------------

This SAB Agreement shall be governed and construed in accordance with laws of
the State of California according to its fair meaning and not in favor of or
against any party.

<PAGE>

X. Acceptance
   ----------

If you are in agreement with the foregoing terms and conditions, then please
sign and date the duplicate originals of this SAB Agreement and appropriate
appendices and return one original agreement with appropriate appendices to the
Company.

Kosan Biosciences, Inc.

By    /s/ Michael S. Ostrach
   --------------------------------------------------
          Michael S. Ostrach
          President and Chief Operating Officer

AGREED AND ACCEPTED

SIGNATURE:                          By:   /s/ Brian W. Metcalf, Ph.D.
                                        ----------------------------------------
                                              Brian W. Metcalf, Ph.D.

DATE:                                       1/23/02
                                        ----------------------------------------

<PAGE>

                                    Exhibit B

                              EMPLOYMENT AGREEMENT

This Agreement, by and between Brian Metcalf, Ph.D. ("Employee") and Kosan
Biosciences, Inc. (the "Company"), is made as of March 17, 2000.

In consideration of the mutual covenants contained in this Agreement, and in
consideration of the employment of Employee by the Company, the parties agree as
follows:

1. Duties and Scope of Employment

(a) Position. The Company agrees to employ Employee under the terms of this
Agreement in the position of Senior Vice President and Chief Scientific Officer
beginning on March 17, 2000 (the "Start Date"). As Senior Vice President and
Chief Scientific Officer, Employee shall manage technology development and drug
discovery research, identify and develop new technology and product-oriented
research programs, manage preclinical development of Company products, establish
effective research infrastructure and administration, and have the other
responsibilities typical of such position. Employee will be a member of the
senior management group and research committee. Employee shall report to the
Chief Executive Officer of the Company.

(b) Obligations. Employee shall devote his efforts full time to the Company, and
shall not engage in any outside activities that interfere or conflict with
Employee's responsibilities to the Company or are inconsistent with the
Company's policies.

2. Compensation

(a) Salary. Beginning on the Start Date, Employee shall be paid a salary of
$280,000 per year, payable semi-monthly in accordance with the Company's payroll
policies and subject to standard payroll deductions and withholdings.

(b) Bonus. Employee will receive a bonus of $100,000 payable after the first two
weeks of employment. Employee will participate in any future incentive or bonus
plan or program at a level commensurate with other senior executives.

3. Stock Option

Employee will be granted a stock option, which shall be an incentive stock
option to the maximum extent permitted by law, to purchase 100,000 shares of
Common Stock of the Company at the fair market value of such shares on the Start
Date. The shares subject to the option will vest over a four-year period as
follows: 25% will vest after one year of employment and 1/48th of the total will
vest each month of employment thereafter, except as otherwise provided in this
Agreement. The option will be granted pursuant to the Company's 1996 Stock
Option Plan and the Company's standard form of stock option agreement except as
such standard form of agreement is modified by the terms of this agreement. The
shares subject to the option shall become fully vested immediately prior to the
consummation of a Change of Control.

<PAGE>

4. Employee Benefits; Moving Costs; Housing Loan

(a) Employee shall be entitled to the full benefits for which Employee is
eligible under the employee benefit plans and executive compensation programs
maintained by the Company, including medical, dental, disability and life
insurance benefits. In addition, Employee will be entitled to accrue 20 vacation
days per calendar year. Employee may carry over vacation from one year to the
next not to exceed 30 days of accrued vacation in any calendar year. The Company
will reimburse the Employee for the cost of medical insurance benefits generally
provided to a spouse to the extent those costs are not otherwise paid by the
Company under its benefit programs.

(b) Employee shall be reimbursed for normal real estate commissions, closing
costs and reasonable packing, shipping, storage, unpacking and insurance
expenses in connection with selling his current residence and obtaining a
permanent residence in the Bay Area.

(c) Employee shall be reimbursed for up to six months of normal temporary
housing costs in the Bay Area incurred by the Employee for himself and his
immediate family.

(d) Employee shall be reimbursed for normal travel and living expenses for two
trips (including your spouse) to the Bay area for the purpose of purchasing a
new principal residence.

(e) Employee shall be entitled to a housing loan of up to $400,000 in connection
with obtaining a permanent residence in the Bay Area. The loan will have a
maximum term of five (5) years (with the due date for full repayment accelerated
to the date of termination if Employee voluntary terminates his employment) at
the lowest annual interest rate necessary to avoid imputed interest. The loan
will be secured by a second mortgage on your primary residence.

(f) Employee shall be entitled to a monthly mortgage assistance payment to
support up to $400,000 of mortgage principal on a 30-year mortgage. Such payment
shall be grossed up for tax purposes by paying Employee an additional 60% of the
amount of the mortgage assistance payment to assist with the payment of tax
liability for such mortgage assistance payment. Such grossed up payment shall
start with the first month such payment is due and shall continue for twelve
months at 100% of the payment, shall continue for the next twelve months at 80%
of the payment, for the next twelve months at 60% of the payment, for the next
twelve months at 40% of the payment and for the next twelve months at 20% of the
payment, at which time such payments shall end. Such payments shall also end at
the termination of Employee's employment at the Company.

5. Proprietary Information Agreement; U.S. Employment Eligibility

Employee agrees to sign and comply with the Company's Proprietary Information
and Inventions Agreement. Employee will provide to the Company documentary
evidence of his identity and eligibility for employment in the United States
within three (3) business days of the Start Date.

<PAGE>

6. Employment at Will: Limitation of Remedies

The Company and Employee acknowledge that Employee's employment is at will and
can be terminated by either party at any time with or without cause. If
Employee's employment terminates for any reason, Employee shall not be entitled
to any payments, benefits, damages, awards or compensation other than as
provided by this Agreement. This at-will relationship supersedes any previous
written or oral statements by the parties and cannot be changed except in
writing signed by Employee and duty authorized officer of the Company.

7. Term of Employment

(a) Voluntary Termination by Employee. Employee may terminate his employment
voluntarily giving the Company 30 days' advance notice in writing. No
compensation or payments will be paid or provided following the date when such a
termination is effective. In lieu of continuing to employ Employee through the
date when such a termination is effective, the Company shall have the option to
terminate Employee's employment immediately upon receipt of such notice,
provided that the Company shall be obligated to continue to pay Employee his
salary, benefits and vacation accruals through the date termination otherwise
would have been effective had the Company not exercised such option. Termination
by the Company pursuant to this Section 7(a) shall not be deemed to be
termination without Cause.

(b) Termination by the Company. The Company may terminate Employee's employment
at any time, for any reason or for no reason.

     (i) Termination for Cause. If the Company terminates Employee's employment
for Cause, no compensation or payments will be provided to Employee following
the date when such a termination of employment is effective. Any remaining
housing loan shall be repaid within six months of the termination date.

     (ii) Termination without Cause. If the Company terminates Employee's
employment without Cause, the provisions of Section 8 and the Definitions of
Section 10 shall apply. Any remaining housing loan shall be converted to a
five-year note at prime plus 1.0%, compounded annually, and the first payment
shall begin one year from the termination date.

8. Payment Upon Termination Without Cause

If Employee's employment is terminated without Cause during the three-year
period following the Start Date, Employee shall be entitled to receive the
following:

(a) Severance Payment. The Company shall continue to pay to Employee his then
current salary for twelve months in monthly installments, and benefits,
following the date when such a termination of employment is effective, provided
that: (i) the Company's obligation to continue to pay such base salary shall
cease as of the date Employee commences full-time employment with another
business entity (and Employee agrees to provide notice of such employment within
three business days of accepting such an offer); and (ii) Employee executes a
waiver and release of claims substantially in the form set forth in Exhibit A
hereto.

<PAGE>

(b) Acceleration of Stock Vesting. If such termination without Cause shall occur
after the twelve month anniversary of the Start Date, all of the shares that
would become vested within six months of such date of termination under the
terms of the option described in Section 3 will be deemed to have vested
provided Employee executes a waiver and release of claims substantially in the
form set forth in Exhibit A hereto.

9. Parachute Payment

Anything in this Agreement to the contrary notwithstanding, if the aggregate of
the amounts due Employee under this Agreement and any other plan, program, or
arrangement of the Company or its Affiliates constitutes a "Parachute Payment"
as such term is defined in Section 280G of the Internal Revenue Code of 1986
(the "Code"), and the amount of the Parachute Payment, reduced by all Federal,
state and local taxes applicable to such payments which are considered to be
contingent on a Change in Control, including the excise tax imposed pursuant to
Section 4999 of the Code, is less than the amount Employee would receive, after
taxes, if he were paid only a dollar amount equal to three times his Base Amount
as defined in Section 280G(b)(3) of the Code less $1.00, then the payments made
to Employee under this Agreement which are contingent on a Change of Control
shall be reduced to an amount which, when added to the aggregate of all other
payments to Employee which are contingent on a Change of Control, will make the
total fair market value of such payments equal to three times his Base Amount
less $1.00, all as determined under Section 280G of the Code.

10. Definitions

As used in this Agreement, the following definitions shall apply

(a) "Cause" shall mean the occurrence of any of the following: (i) any breach by
Employee of this agreement or his obligations to the Company under the Employee
Proprietary Information and Invention Assignment Agreement which is not cured
within 30 days after notice of breach is provided to Employee by the Company,
(ii) Employees's conviction of a felony or crime involving moral turpitude,
(iii) any action by Employee prior to or during his employment which in the
reasonable judgment of the Company constitutes dishonesty, larceny, fraud,
deceit or gross negligence by Employee in the performance of his duties to the
Company, or willful misconduct or misrepresentation in connection with, or in
the course of, his duties and responsibilities, or (iv) Employee's gross
insubordination or gross refusal to perform reasonable and lawful directives
from his superiors, which is not corrected within 30 day after written notice.

(b) "Change in Control" shall mean the occurrence of any of the following: (i)
the Company enters into a reorganization (as defined in Section 181 of the
California Corporations Code) with or into another corporation or entity (except
where California Corporations Code Section 1201(b) does not require the approval
of the outstanding shares of the Company with respect to such reorganization),
(ii) the Company sells all or substantially all of its assets, (iii) a person or
entity makes a tender or exchange offer for and acquires 50% or more of the
issued and

<PAGE>

outstanding voting securities of the Company, or (iv) any person, within the
meaning of Section 3(a)(9) or Section 13(d)(3) of the Securities Exchange Act of
1934, as amended, acquires more than 50% of the issued and outstanding voting
securities of the Company.

11. Other Agreements

Employees represents and warrants the Employee's performance of his duties for
the Company will not violate any agreements, obligations or understandings that
he may have with any third party or prior employer. Employee agrees not to make
any unauthorized disclosure or use, on behalf of the Company, of any
confidential information belonging to any of Employee's former employers.
Employee also represents that he is not in authorized possession of any
materials containing a third party's confidential and proprietary information.
During Employee's employment with the Company, Employee may make use of
information general known and used by persons with training and experience
comparable to Employee's own, and information which is common knowledge in the
industry or is otherwise legally available in the public domain.

12. Arbitration

In the event of any dispute or claim relating to or arising out of this
Agreement, Employee and the Company agree that all such disputes shall be fully
and finally resolved by binding arbitration conducted by the American Arbitation
Association in San Francisco, California. However, this arbitration provision
shall not apply to any disputes or claims relating to or arising out of the
misuse or misappropriation of the Company's trade secrets or proprietary
information.

13. Governing Law

This Agreement shall be governed by the laws of the State of California as
applied to agreements and entered into by California residents and to be
performed entirely within the State of California.

14. Expiration of Offer

This offer of employment expires at midnight on May 1, 2000.

15. Entire Agreement

This Agreement constitutes the complete, final exclusive embodiment of the
entire agreement between Employee and the Company with respect to the terms and
conditions of Employee's employment. Employee represents and warrants that he is
entering into this Agreement voluntarily, and without reliance upon any promise,
warranty or representation, written or oral, other than those expressly
contained herein. This Agreement supersedes any other such promises, warranties,

<PAGE>

representations or agreements. This Agreement may not be amended or modified
except by a written instrument signed by Employee and duly authorized officer of
the Company.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
date first set forth above.

KOSAN BIOSCIENCES, INC.

By:  /s/ Daniel V. Santi, M.D., Ph.D.
   -----------------------------------------
         Daniel V. Santi, M.D., Ph.D.
         Chairman and Chief Executive Officer

By:  /s/ Brian W. Metcalf, Ph.D.
   ---------------------------------
         Brian W. Metcalf, Ph.D.

<PAGE>
                                    EXHIBIT C

                                   PRIOR NOTE

                                 PROMISSORY NOTE

$400,000.00                                                         May 30, 2000
                               Hayward, California

     FOR VALUE RECEIVED, Brian Metcalf ("Employee"), an employee of Kosan
Biosciences, Inc. ("Company"), hereby unconditionally promises to pay to the
order of Company, in lawful money of the United States of America and in
immediately available funds, the principal sum of Four Hundred Thousand Dollars
($400,000.00) (the "Loan") due and payable on the date and in the manner set
forth below.

1. Intent. It is the intent of the parties that the purpose of this Note is not
for consumer, family or household purposes.

2. Principal Repayment. The outstanding principal amount of the Loan shall be
due and payable on the earlier of the following (the "Maturity Date"): (a) May
30, 2005; or (b) the date on which Employee voluntarily terminates his
employment relationship with Company.

3. Interest Rate. Employee further promises to pay interest on the outstanding
principal amount hereof from the date hereof until payment in full, which
interest shall be payable at the rate of 6.3% per annum compounded annually.
Interest shall be due and payable on the Maturity Date and shall be calculated
on the basis of a 360-day year for the actual number of days elapsed.

4. Place of Payment; Prepayment. All amounts payable hereunder shall be payable
at the office of Company unless another place of payment shall be specified in
writing by Company. Prepayment is permitted.

5. Application of Payments. Payment on this Note shall be applied first to
accrued interest, if any, and thereafter to the outstanding principal balance
hereof.

6. Default. Each of the following events shall be an "Event of Default"
hereunder:

(a) Employee fails to pay timely any of the principal amount due under this Note
on the date the same becomes due and payable or any accrued interest or other
amounts due under this Note, if any, on the date the same becomes due and
payable, or fails to perform any other obligations hereunder;

(b) Employee files a petition or action for relief under any bankruptcy,
insolvency or moratorium law or any other law for the relief of, or relating to,
debtors, now or hereafter in effect, or makes any assignment for the benefit of
creditors or takes any action in furtherance of any of the foregoing;

<PAGE>

(c) An involuntary petition is filed against Employee (unless such petition is
dismissed or discharged within sixty (60) days) under any bankruptcy statute now
or hereafter in effect, or a custodian, receiver, trustee, assignee for the
benefit of creditors (or other similar official) is appointed to take
possession, custody or control of any property of Employee; or

(d) Employee's employment by or association with the Company is terminated for
any reason or no reason, including, without limitation, death of Employee.

Upon the occurrence of an Event of Default hereunder, all unpaid principal,
accrued interest and other amounts owing hereunder, if any, shall, at the option
of Company, and, in the case of an Event of Default pursuant to (b) or (c)
above, automatically, be immediately due, payable and collectible by Company
pursuant to applicable law. Notwithstanding the foregoing, if an Event of
Default has occurred under (d) above due to the Company's termination of
Employee's employment with the Company without cause, this Note shall be
converted to a five (5) year note at an interest rate equal to the Prime Rate
plus one percent (1%), compounded annually, and the principal shall be payable
in five equal annual installments, together with interest thereon payable in
arrears calculated on the basis of a 360 day year for the actual number of days
elapsed, beginning one year from such date of termination of employment. The
Prime Rate shall mean the variable rate of interest, per annum, most recently
published in the Money Rate Section of the New York Edition of The Wall Street
Journal, as the "prime rate". If an Event of Default has occurred under (d)
above due to the Company's termination of Employee's employment with the Company
for cause, all unpaid principal and accrued interest shall be due and payable
within six (6) months from such date of Employee's termination of employment.
The Company shall have all rights and may exercise any remedies available to it
under law, successively or concurrently. Employee expressly acknowledges and
agrees that Company shall have the right to offset any obligations of Employee
hereunder against salaries, bonuses or other amounts that may be payable to
Employee by Company.

7. Waiver. Employee waives presentment and demand for payment, notice of
dishonor, protest and notice of protest of this Note, and shall pay all costs of
collection when incurred, including, without limitation, reasonable attorneys'
fees, costs and other expenses. The right to plead any and all statutes of
limitations as a defense to any demands hereunder is hereby waived to the full
extent permitted by law.

8. Governing Law. This Note shall be governed by, and construed and enforced in
accordance with, the laws of the State of California, excluding conflict of laws
principles that would cause the application of laws of any other jurisdiction.

9. Successors and Assigns. The provisions of this Note shall inure to the
benefit of and be binding on any successor to Employee and shall extend to any
holder hereof. Employee shall not, without the prior written consent of holder,
assign any of its rights or obligations hereunder.

Dated: May 30, 2000

By:   /s/ Brian W. Metcalf, Ph.D.
   ---------------------------------
       Brian W. Metcalf, Ph.D.

<PAGE>

                                    EXHIBIT D

                                 PROMISSORY NOTE

$434,224.00                                                     January 29, 2001
                               Hayward, California

     FOR VALUE RECEIVED, Brian Metcalf (the "Debtor") hereby unconditionally
promises to pay to Kosan Biosciences Incorporated (the "Company"), or order, in
lawful money of the United States of America and in immediately available funds,
the principal sum of Four Hundred Thirty Four Thousand Twenty Four Dollars
($434,224.00) (the "Loan") due and payable on the date and in the manner set
forth below.

1. Principal Repayment. The outstanding principal amount of the Loan shall be
due and payable in accordance with the payment schedule in Appendix A attached.

2. Interest Rate. Debtor further promises to pay interest on the outstanding
principal amount hereof from the date hereof until payment in full, which
interest shall be payable at the rate of five and seventy-five one hundredths
percent (5.75%) per annum compounded annually.

3. Place of Payment; Prepayment. All amounts payable hereunder shall be payable
at the office of Company unless another place of payment shall be specified in
writing by Company. Prepayment is permitted.

4. Default. Each of the following events shall be an "Event of Default"
hereunder:

(a) Debtor fails to pay timely any of the principal amount due under this Note
on the date(s) the same becomes due and payable or any accrued interest or other
amounts due under this Note, if any, on the date(s) the same becomes due and
payable, or fails to perform any other obligations hereunder;

(b) Debtor files a petition or action for relief under any bankruptcy,
insolvency or moratorium law or any other law for the relief of, or relating to,
debtors, now or hereafter in effect, or makes any assignment for the benefit of
creditors or takes any action in furtherance of any of the foregoing;

(c) An involuntary petition is filed against Debtor (unless such petition is
dismissed or discharged within sixty (60) days) under any bankruptcy statute now
or hereafter in effect, or a custodian, receiver, trustee, assignee for the
benefit of creditors (or other similar official) is appointed to take
possession, custody or control of any property of Debtor; or

(d) Debtor's association with the Company is terminated for any reason or no
reason, including, without limitation, death of Debtor.

<PAGE>

Upon the occurrence of an Event of Default hereunder, all unpaid principal,
accrued interest and other amounts owing hereunder, if any, shall, at the option
of Company, and, in the case of an Event of Default pursuant to (b) or (c)
above, automatically, be immediately due, payable and collectible by Company
pursuant to applicable law. Notwithstanding the foregoing, if an Event of
Default has occurred under (d) above due to the Company's termination of
Debtor's consulting agreement with the Company for cause, all unpaid principal
and accrued interest shall be due and payable within six (6) months from such
date of Debtor's termination of consulting. The Company shall have all rights
and may exercise any remedies available to it under law, successively or
concurrently. Debtor expressly acknowledges and agrees that Company shall have
the right to offset any obligations of Debtor hereunder against any salaries,
bonuses or other amounts that may be payable to Debtor by Company.

5. Waiver. Debtor waives presentment and demand for payment, notice of dishonor,
protest and notice of protest of this Note, and shall pay all costs of
collection when incurred, including, without limitation, reasonable attorneys'
fees, costs and other expenses. The right to plead any and all statutes of
limitations as a defense to any demands hereunder is hereby waived to the full
extent permitted by law.

6. Governing Law. This Note shall be governed by, and construed and enforced in
accordance with, the laws of the State of California, excluding conflict of laws
principles that would cause the application of laws of any other jurisdiction.

7. Successors and Assigns. The provisions of this Note shall inure to the
benefit of and be binding on any successor to Debtor and shall extend to any
holder hereof. Debtor shall not, without the prior written consent of holder,
assign any of its rights or obligations hereunder.

Dated: January 29, 2002

By:   /s/ Brian W. Metcalf, Ph.D.
   ----------------------------------
       Brian W. Metcalf, Ph.D.

<PAGE>

                                   APPENDIX A

                Brian W. Metcalf Promissory Note Payment Schedule

Principal:               $ 434,224
Interest:                    5.75%

<TABLE>
<CAPTION>
    Payment                                                              5.75%                               Running
      No.         Due Date         Days             Principal          Interest          Payment             Balance
-----------------------------------------------------------------------------------------------------------------------------
<S>               <C>             <C>             <C>                  <C>             <C>                <C>
                  1/29/02                         $ 434,224.00                                            $ 434,224.00
      1           1/29/03         365.00            434,224.00         25,314.66        10,710.00           448,828.66
      2           2/28/03          30.00            448,828.66          2,150.64        10,710.00           440,269.29
      3           3/29/03          29.00            440,269.29          2,039.30        10,710.00           431,598.60
      4           4/29/03          31.00            431,598.60          2,137.01        10,710.00           423,025.61
      5           5/29/03          30.00            423,025.61          2,027.00        10,710.00           414,342.61
      6           6/29/03          31.00            414,342.61          2,051.57        10,710.00           405,684.18
      7           7/29/03          30.00            405,684.18          1,943.90        10,710.00           396,918.08
      8           8/29/03          31.00            396,918.08          1,965.30        10,710.00           388,173.38
      9           9/29/03          31.00            388,173.38          1,922.00        10,710.00           379,385.37
     10          10/29/03          30.00            379,385.37          1,817.89        10,710.00           370,493.26
     11          11/29/03          31.00            370,493.26          1,834.46        10,710.00           361,617.72
     12          12/29/03          30.00            361,617.72          1,732.75        10,710.00           352,640.47
     13           1/29/04          31.00            352,640.47          1,746.06        10,710.00           343,676.53
     14           2/29/04          31.00            343,676.53          1,701.68        10,710.00           334,668.21
     15           3/29/04          29.00            334,668.21          1,550.16        10,710.00           325,508.37
     16           4/29/04          31.00            325,508.37          1,611.72        10,710.00           316,410.09
     17           5/29/04          30.00            316,410.09          1,516.13        10,710.00           307,216.22
     18           6/29/04          31.00            307,216.22          1,521.15        10,710.00           298,027.37
     19           7/29/04          30.00            298,027.37          1,428.05        10,710.00           288,745.42
     20           8/29/04          31.00            288,745.42          1,429.69        10,710.00           279,465.11
     21           9/29/04          31.00            279,465.11          1,383.74        10,710.00           270,138.85
     22          10/29/04          30.00            270,138.85          1,294.42        10,710.00           260,723.26
     23          11/29/04          31.00            260,723.26          1,290.94        10,710.00           251,304.21
     24          12/29/04          30.00            251,304.21          1,204.17        10,710.00           241,798.37
     25           1/29/05          31.00            241,798.37          1,197.24        10,710.00           232,285.61
     26           2/28/05          30.00            232,285.61          1,113.04        10,710.00           222,688.64
     27           3/29/05          29.00            222,688.64          1,031.48        10,710.00           213,010.13
     28           4/29/05          31.00            213,010.13          1,054.70        10,710.00           203,354.82
     29           5/29/05          30.00            203,354.82            974.41        10,710.00           193,619.23
     30           6/29/05          31.00            193,619.23            958.68        10,710.00           183,867.91
     31           7/29/05          30.00            183,867.91            881.03        10,710.00           174,038.95
</TABLE>

<PAGE>
<TABLE>
<S>               <C>              <C>             <C>                  <C>             <C>                <C>
     32          8/29/05           31.00            174,038.95            861.73        10,710.00           164,190.68
     33          9/29/05           31.00            164,190.68            812.97        10,710.00           154,293.65
     34         10/29/05           30.00            154,293.65            739.32        10,710.00           144,322.98
     35         11/29/05           31.00            144,322.98            714.60        10,710.00           134,327.58
     36         12/29/05           30.00            134,327.58            643.65        10,710.00           124,261.23
     37          1/29/06           31.00            124,261.23            615.27        10,710.00           114,166.50
     38          2/28/06           30.00            114,166.50            547.05        10,710.00           104,003.54
     39          3/29/06           29.00            104,003.54            481.74        10,710.00            93,775.28
     40          4/29/06           31.00             93,775.28            464.32        10,710.00            83,529.60
     41          5/29/06           30.00             83,529.60            400.25        10,710.00            73,219.85
     42          6/29/06           31.00             73,219.85            362.54        10,710.00            62,872.39
     43          7/29/06           30.00             62,872.39            301.26        10,710.00            52,463.65
     44          8/29/06           31.00             52,463.65            259.77        10,710.00            42,013.42
     45          9/29/06           31.00             42,013.42            208.02        10,710.00            31,511.44
     46         10/29/06           30.00             31,511.44            150.99        10,710.00            20,952.43
     47         11/29/06           31.00             20,952.43            103.74        10,710.00            10,346.18
     48         12/29/06           30.00             10,346.18             49.58        10,395.75                 0.00
</TABLE>

<PAGE>

                                    EXHIBIT E

                    FORM OF EMPLOYEE PROPRIETARY INFORMATION
                       AND INVENTION ASSIGNMENT AGREEMENT

                         KOSAN BIOSCIENCES INCORPORATED

                      EMPLOYEE PROPRIETARY INFORMATION AND
                         INVENTION ASSIGNMENT AGREEMENT

     As an employee of Kosan Biosciences Incorporated, a California corporation,
its subsidiary or its affiliate (together, the "Company"), in consideration of
my employment with the Company as previously agreed by me in my employment
letter with the Company and in consideration of the compensation now and
hereafter paid to me, I agree to the following:

     1. Maintaining Confidential Information
        ------------------------------------

          a. Company Information. I agree at all times during the term of my
             -------------------
employment and thereafter to hold in strictest confidence, and not to use,
except for the benefit of the Company, or to disclose to any person, firm or
corporation without written authorization of the Company, any trade secrets,
confidential knowledge, data or other proprietary information relating to
products, processes, know-how, designs, formulas, developmental or experimental
work, computer programs, data bases, other original works of authorship,
customer lists, business plans, financial information or other subject matter
pertaining to any business of the Company or any of its clients, consultants, or
licensees.

          b. Former Employer Information. I agree that I will not, during my
             ---------------------------
employment with the Company, improperly use or disclose any proprietary
information or trade secrets of my former or concurrent employers or companies,
or any other person, and that I will not bring onto the premises of the Company
any unpublished document or any property belonging to my former or concurrent
employers or companies, or any other person, unless consented to in writing by
said employers, companies, or other person.

          c. Third-Party Information. I recognize that the Company has received
             -----------------------
and in the future will receive from third parties their confidential or
proprietary information subject to a duty on the Company's part to maintain the
confidentiality of such information and to use it only for certain limited
purposes. I agree that I owe the Company and such third parties, during the term
of my employment and thereafter, a duty to hold all such confidential or
proprietary information in the strictest confidence and not to disclose

<PAGE>

it to any person, firm or corporation (except as necessary in carrying out my
work for the Company consistent with the Company's agreement with such third
party) or to use it for the benefit of anyone other than for the Company or such
third party (consistent with the Company's agreement with such third party)
without the express written authorization of the Company.

     2. Retaining and Assigning Inventions and Original Works
        -----------------------------------------------------

          a. Inventions and Original Works Retained by Me. I have listed in
             --------------------------------------------
Section 7 hereof descriptions of any and all inventions, original works of
authorship, developments, improvements, and trade secrets belonging to me which
were made by me prior to my employment with the Company, which relate to the
Company's proposed business and products, and which are not assigned to the
Company (collectively, "Prior Inventions").

          b. Inventions and Original Works Assigned to the Company. I agree that
             -----------------------------------------------------
I will promptly make full written disclosure to the Company, will hold in trust
for the sole right and benefit of the Company, and will assign to the Company
all my right, title, and interest in and to any and all inventions, original
works of authorship, developments, improvements or trade secrets which I may
solely or jointly conceive or develop or reduce to practice, or cause to be
conceived or developed or reduced to practice, during the period of time I am in
the employ of the Company (collectively, "Company Inventions"). I recognize,
however, that assignment to the Company under this provision of any invention is
subject to Section 2870 of the California Labor Code, which reads as follows:

               "(a) Any provision in an employment agreement which provides that
an employee shall assign, or offer to assign, any of his or her rights in an
invention to his or her employer shall not apply to an invention that the
employee developed entirely on his or her own time without using the employer's
equipment, supplies, facilities, or trade secret information except for those
inventions that either:

                    (1) Relate at the time of conception or reduction to
practice of the invention to the employer's business, or actual or demonstrably
anticipated research or development of the employer.

                    (2) Result from any work performed by the employee for the
employer.

               "(b) To the extent a provision in an employment agreement
purports to require an employee to assign an invention otherwise excluded from
being required to be assigned under subdivision (a), the provision is against
the public policy of this state and unenforceable."

<PAGE>

     I agree to grant the Company or its designees a royalty free, irrevocable,
worldwide license (with rights to sublicense through multiple tiers of
distribution) to practice all applicable patent, copyright and other
intellectual property rights relating to any Prior Inventions that I
incorporate, or permit to be incorporated, in any Company Invention.
Notwithstanding the foregoing, I agree that I will not incorporate, or permit to
be incorporated, any Prior Invention in any Company Invention without the
Company's prior written consent.

     I acknowledge that all original works of authorship which are made by me
(solely or jointly with others) within the scope of my employment and which are
protectable by copyright are "works made for hire," as the term is defined in
the United States Copyright Act (17 USCA, Section 101).

          c. Maintenance of Records. I agree to keep and maintain adequate and
             ----------------------
current written records of all inventions and original works of authorship made
by me (solely or jointly with others) during the term of my employment with the
Company. The records will be in the form of notes, sketches, drawings, and any
other format that may be specified by the Company. The records will be available
to and remain the sole property of the Company at all times.

          d. Inventions Assigned to the United States. I agree to assign to the
             ----------------------------------------
United States government all my right, title, and interest in and to any and all
inventions, original works of authorship, developments, improvements or trade
secrets whenever such full title is required to be in the United States by a
contract between the Company and the United States or any of its agencies.

          e. Obtaining Letters Patent, Copyrights, and Mask Work Rights. I agree
             ----------------------------------------------------------
that my obligation to assist the Company to obtain United States or foreign
letters patent, copyrights, or mask work rights covering inventions, works of
authorship, and mask works, respectively, assigned hereunder to the Company
shall continue beyond the termination of my employment, but the Company shall
compensate me at a reasonable rate for time actually spent by me at the
Company's request on such assistance. If the Company is unable because of my
mental or physical incapacity or for any other reason to secure my signature to
apply for or to pursue any application for any United States or foreign letters
patent, copyrights, or mask work rights covering inventions or other rights
assigned to the Company as above, then I hereby irrevocably designate and
appoint the Company and its duly authorized officers and agents as my agent and
attorney in fact, to act for and in my behalf and stead to execute and file any
such applications and to do all other lawfully permitted acts to further the
prosecution and issuance of letters patent, copyrights, and mask work rights
with the same legal force and effect as if executed by me. I hereby waive and
quitclaim to the Company any and all claims, of any nature whatsoever, which I
now

<PAGE>

or may hereafter have, of infringement of any patents, copyrights, or mask work
rights resulting from any such application assigned hereunder to the Company.

          f. Exception to Assignments. I understand that the provisions of this
             ------------------------
agreement requiring assignment to the Company do not apply to any invention
which qualifies fully under the provisions of Section 2870 of the California
Labor Code. I will advise the Company promptly in writing of any inventions,
original works of authorship, developments, improvements or trade secrets that I
believe are exempt from assignment to the Company based upon the application of
Section 2870 of the California Labor Code; and I will at that time provide to
the Company in writing all evidence necessary to substantiate that belief. I
understand that the Company will keep in confidence and will not disclose to
third parties without my consent any confidential information disclosed in
writing to the Company relating to inventions that qualify fully under the
provisions of Section 2870 of the California Labor Code.

     3. Conflicting Employment. I agree that, during the term of my employment
        ----------------------
with the Company, I will not engage in any other employment, occupation,
consulting or other business activity directly related to the business in which
the Company is now involved or becomes involved during the term of my
employment, nor will I engage in any other activities that conflict with my
obligations to the Company.

     4. Company Documents and Property. I agree that, at the time of leaving the
        ------------------------------
employ of the Company, I will deliver to the Company (and will not keep in my
possession or deliver to anyone else) any and all devices, records, data, notes,
reports, proposals, lists, correspondence, specifications, drawings, blueprints,
sketches, materials, equipment, other documents or property, or reproductions of
any aforementioned items belonging to the Company, its successors or assigns. I
further agree that any property situated on the Company's premises and owned by
the Company, including desks, filing cabinets, or other storage or work areas,
is subject to inspection by Company personnel at any time with or without
notice.

     5. Representations. I agree to execute any proper oath or verify any proper
        ---------------
document required to carry out the terms of this agreement. I represent that my
performance of all the terms of this agreement will not breach any agreement to
keep in confidence proprietary information acquired by me in confidence or in
trust prior to my employment by the Company. I have not entered into, and I
agree I will not enter into, any oral or written agreement in conflict herewith.

<PAGE>

     6. General Provisions
        ------------------

          a. Governing Law. This agreement will be governed by and construed in
             -------------
accordance with the laws of the State of California as such laws are applied to
agreements entered into and to be performed entirely within California by
California residents.

          b. Entire Agreement; Amendment. This agreement sets forth the entire
             ---------------------------
agreement and understanding between the Company and me relating to the subject
matter herein and merges all prior discussions between us. No modification of or
amendment to this agreement, nor any waiver of any rights under this agreement,
will be effective unless in writing signed by the party to be charged. Any
subsequent change or changes in my duties, salary or compensation will not
affect the validity or scope of this agreement.

          c. Severability. If one or more of the provisions in this agreement
             ------------
are deemed void by law, then the remaining provisions will continue in full
force and effect.

          d. Successors and Assigns. This agreement will be binding upon my
             ----------------------
heirs, executors, administrators and other legal representatives and will be for
the benefit of the Company, its successors, and its assigns.

          e. Survival. The provisions of this agreement shall survive the
             --------
termination of my employment and the assignment of this agreement by the Company
to any successor in interest or other assignee. This agreement is binding upon
my heirs and legal representatives.

          f. Employment. As used herein, my employment includes any time during
             ----------
which I may be retained by the Company as a consultant. I agree and understand
that nothing in this agreement shall confer any right with respect to
continuation of employment by the Company, nor shall it interfere in any way
with my right or the Company's right to terminate my employment at any time,
with or without cause.

          g. No Solicitation. During the term of my employment with the Company
             ---------------
and for a period of two years thereafter, I will not solicit, encourage, or
cause others to solicit or encourage any employees of the Company to terminate
their employment with the Company.

          h. Injunctive Relief. I agree that a breach of any of the
             -----------------
representations, warranties or covenants contained in this agreement will result
in irreparable and continuing damage to the Company for which there will be no
adequate remedy at law, and that consequently the Company will be entitled to
injunctive relief and/or a decree for specific performance and such other relief
as may be proper (including monetary damages if appropriate).

<PAGE>

          i. Waiver. The waiver by the Company of a breach of any provision of
             ------
this agreement by me will not operate or be construed as a waiver of any other
or subsequent breach by me.

     7. List of Inventions. Pursuant to Section 2(a) of this agreement, set
        ------------------
forth below is a list of my prior inventions and original works of authorship:

        Title             Date                              Brief Description
        -----             ----                              -----------------

<PAGE>

IF NO PRIOR INVENTIONS OR ORIGINAL WORKS OF AUTHORSHIP ARE LISTED IN THIS
SECTION 7, I HEREBY AFFIRM THAT THERE ARE NO SUCH INVENTIONS OR ORIGINAL WORKS
OF AUTHORSHIP.

KOSAN BIOSCIENCES INCORPORATED

By:  /s/ Michael S. Ostrach
   ---------------------------------
         Michael S. Ostrach
         Chief Operating Officer

Dated:   March 28, 2000
        ----------------------------

ACCEPTED AND AGREED:

By:  /s/ Brian W. Metcalf, Ph.D.
   ---------------------------------
         Brian W. Metcalf, Ph.D.

Dated:   March 28, 2000
        ----------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}]]